Hamel Associates Inc. acquired a new stake in shares of AstraZeneca Plc (NYSE:AZN – Free Report) in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund acquired 4,003 shares of the company’s stock, valued at approximately $646,000.
Other large investors have also made changes to their positions in the company. Moors & Cabot Inc. acquired a new stake in shares of AstraZeneca in the third quarter worth $1,155,000. William Blair Investment Management LLC purchased a new stake in AstraZeneca in the third quarter valued at $90,809,000. Allworth Financial LP boosted its holdings in AstraZeneca by 313.0% in the third quarter. Allworth Financial LP now owns 33,413 shares of the company’s stock valued at $5,395,000 after purchasing an additional 25,322 shares during the last quarter. GKV Capital Management Co. Inc. grew its position in AstraZeneca by 14.8% during the 3rd quarter. GKV Capital Management Co. Inc. now owns 12,905 shares of the company’s stock worth $2,100,000 after purchasing an additional 1,660 shares during the period. Finally, Fisher Asset Management LLC grew its position in AstraZeneca by 3.2% during the 3rd quarter. Fisher Asset Management LLC now owns 11,501,748 shares of the company’s stock worth $1,857,187,000 after purchasing an additional 355,456 shares during the period. 20.35% of the stock is owned by hedge funds and other institutional investors.
AstraZeneca Price Performance
NYSE:AZN opened at $184.66 on Monday. AstraZeneca Plc has a 52 week low of $153.41 and a 52 week high of $212.71. The company has a quick ratio of 0.79, a current ratio of 1.01 and a debt-to-equity ratio of 0.51. The stock has a market capitalization of $286.40 billion, a PE ratio of 26.12, a price-to-earnings-growth ratio of 1.43 and a beta of 0.24. The stock’s 50-day moving average price is $168.82 and its 200-day moving average price is $180.20.
AstraZeneca (NYSE:AZN – Get Free Report) last announced its quarterly earnings results on Saturday, October 31st. The company reported $2.79 earnings per share for the quarter, beating the consensus estimate of $2.60 by $0.19. The firm had revenue of $16.21 billion during the quarter, compared to analyst estimates of $16 billion. AstraZeneca had a return on equity of 31.85% and a net margin of 17.68%. AstraZeneca’s revenue for the quarter was up 6.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.38 EPS. As a group, equities analysts expect that AstraZeneca Plc will post 10.22 EPS for the current fiscal year.
Analyst Ratings Changes
A number of equities analysts have weighed in on AZN shares. Nordea Equity Research upgraded AstraZeneca from a “sell” rating to a “buy” rating in a research note on Tuesday, October 13th. Wall Street Zen upgraded AstraZeneca from a “hold” rating to a “buy” rating in a research report on Saturday, October 31st. CICC Research assumed coverage on AstraZeneca in a research report on Sunday, August 23rd. They set an “outperform” rating and a $198.00 price target for the company. Weiss Ratings raised AstraZeneca from a “hold (c+)” rating to a “buy (b-)” rating in a report on Monday, October 26th. Finally, Deutsche Bank upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research report on Tuesday, September 15th. Sixteen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $206.67.
View Our Latest Stock Report on AZN
About AstraZeneca
AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries. AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.
Further Reading
- Five stocks we like better than AstraZeneca
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca Plc (NYSE:AZN – Free Report).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.
